Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.60 |
| ▸ | BACE1 | P56817 | 10/20 | 0.60 |
| ▸ | BCHE | P06276 | 9/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | FABP6 | P51161 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16269315 | 1.00 | ACHE (0.60) | ACHEBACE1BCHEDRD4TEAD1 | |
| SCHEMBL994595 | 0.91 | ACHE (0.54) | ACHEBACE1BCHEDRD4FABP6 | |
| SCHEMBL2241661 | 0.91 | ACHE (0.54) | ACHEBACE1BCHEDRD4FABP6 | |
| SCHEMBL377906 | 0.91 | DRD4 (0.64) | ACHEBACE1BCHEDRD4TEAD1 | |
| SCHEMBL1562904 | 0.90 | ACHE (0.52) | ACHEBACE1BCHEDRD4FABP6 | |
| SCHEMBL20766057 | 0.87 | BCHE (0.59) | ACHEBACE1BCHEDRD4TEAD1 | |
| SCHEMBL4080791 | 0.85 | FABP6 (0.60) | ACHEBACE1BCHEDRD4FABP6 | |
| SCHEMBL11889388 | 0.85 | DRD4 (0.49) | ACHEBACE1BCHEDRD4FABP6 | |
| SCHEMBL11889448 | 0.85 | DRD4 (0.49) | ACHEBACE1BCHEDRD4FABP6 | |
| SCHEMBL28885289 | 0.84 | SMN1; SMN2 (0.60) | ACHEBACE1BCHEDRD4NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-7619096-B2 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1638934-B1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | LILLY CO ELI (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
| EP-1638934-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000811-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | SLC6A2, SLC6A3, SLC18A2 | ACHE 393/4885BACE1 2336/4885BCHE 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.